Curriculum Vitae

Business Address

David T. Price, MD PA
1111 W. Frank Ave Ste 303
Lufkin, TX 75904
Phone: 936-632-0074
Fax: 936-632-0081

Education

1981-1985 Northeast Louisiana University. Monroe, Louisiana, Bachelor of Science, Zoology, Magna Cum Laude

1985-1989 Louisiana State University Medical School Shreveport,Louisiana. Doctor of Medicine, Alpha Omega Alpha

Professional Training

1990 Intern in Surgery, Duke University Medical Center

1991 Junior Assistant Resident in Surgery, Duke University Medical Center

1994 Fellow in Urologic Oncology, Duke University Medical Center

1994-1996 Senior Resident in Urologic Surgery, Duke University Medical Center

1996-1997Chief Resident in Urologic Surgery, Duke University Medical Center

1997-1999American Foundation of Urologic Disease, Research Scholar in Urologic Oncology, Duke University Medical Center

Professional Appointments and Record of Employment

1997-2000 Assistant Professor of Urology, Duke University Medical Center

1997-2000 Staff Surgeon in Urology, Durham VA Medical Center Consultant in Urology, Asheville VA Medical Center

1998-2000 Duke Comprehensive Cancer Center, Genitourinary Oncology Program, Duke University Medical Center

2000 Assistant Professor of Pharmacology & Cancer Biology, Duke University Medical Center

2000-2007 Regional Urology, Inc. Shreveport, Louisiana

2007-2010 Diagnositic Clinic of Longview, Longview,Texas

2010-present David T. Price, MD PA, Urology, Lufkin, Texas

Honors and Awards

CaPCURE Young Investigator Award, 1999

Montegue Boyd Essay Contest Award, 1999

National Institute of Health Career Development Award 1998

Pfizer Scholar in Urology Award, 1997

American Foundation of Urologic Disease Research Scholar, 1997

Urology Resident Award 1994

Montegue Boyd Essay Contest Award 1993

Alpha Omega Alpha Honor Society 1988

Phillip H. Jones Academic Scholarship 1988-1989

Bernstien Academic Scholarship 1987-1989

George D. Stewart Award for Excellence in the Study of Human Anatomy 1986

Alpha Epsilon Delta Honor Society

National Health Services Scholarship 1985

Department of Biology Oustanding Senior 1985

Magna Cum Laude Graduate 1985

Ana Myers Academic Scholarship 1982-1985

T.H. Harris Academic Scholarship 1981-1985

Research Experience

Research Fellow in Urologic Surgery

Dr. Robert J. Lefkowitz

Howard Hughes Medical Institute

Duke University Medical Center

Associations and Societies

Society of Urologic Oncology

Society of Surgical Oncology

Southeast Section American Urologist Association

American Urological Association

Society of Laparoscopic Surgeons

American Board of Urology Certificate No. 12645 (Expires Feb 2011)

Committees

Clinical Cancer Committee, DUMC 1997-2000

Perioperative Advisory Committee, DUMC 1998

Patient Education Committee VA Medical Center, Durham, NC 1998

Cancer Center Scientific Review Committee, DUMC 1999-2000

Urology Quality Assurance Committee, DUMC 1999-2000

American Cancer Society Institutional Grant Review Committee, 2000

Medical License

North Carolina Medical License No. 97-00369, On Hold

Louisiana State Medical License No. 002511

Texas Medical License No. M7537, (Expires May 2011)

Grants and Funding

American Foundation of Urologic Diseases Research Scholar Award, 1997-1999. Award $44,000.

National Institute of Health, K08 Clinical Scientist Development Award, Awarded September 1998. “Prostate Growth Regulation." Award $593,066. Leave of Absence 2000-2001.

Duke Comprehensive Cancer Center Discovery Award, Awarded June 1999. Dissecting the Role of Telomerase Protein hTERT in the Generation and Treatment of Human Prostate Cancer. Co-investigator with Chris Counter and Mark Dewhirst. $26,800 award.

VA Cooperative Research Award. Study of prostate cancer CAG repeats in the androgen receptor of black and white US veterans. Co-Investigator.

Gaston County Cancer Society Research Award 1999. Inhibition of of prostate cancer progression to androgen independence. Principle Investigator. Award $2,500.

CaPCURE Young Investigator Award 1999. Mitogenic Signal Transduction in Prostate Cancer. Principle Invesigator. Award $150,000

Patent Applications

F18 Labelled Choline Analogues for PET Imaging in Oncology. Co-Inventor with Timothy DeGrado, Edward Coleman and Steve Baldwin. May 2000.

ZAG: A New Serum Marker of Prostate Cancer. Co-Inventor with Laura Hale. November 2000.

Invitational Lectures

Duke Tuesday Urologic Conference on α1-Adrenergic Receptor Subtypes in the Prostate. June 1992, Durham, NC.

Pfizer Central Research Symposium on G Protein-Coupled Receptors, November 17, 1992, Groton, CT.

Merck, Sharp & Dohme Invitational Seminar on Medical Management of Benign Prostatic Hyperplasia, Februrary 19, 1993, Rahway, NJ.

Glaxo Invitational Seminar on Adrenergic Receptor Subtypes and Benign Prostatic Hyperplasia, June23, 1993, RTP, NC.

Louisiana State University Medical Center Shreveport, Urology Grand Rounds Adrenergic Receptor Subtypes and their Clinical Implications in Genitourinary Diseases, November, 1996, Shreveport, Louisiana, 1997.

NCAPA Winter Conference and Recertification Exam Review. Common Urological Problems. February 24, 1998. Research Triangle Park, North Carolina.

Boehringer Ingelheim Speaker Meeting. Adrenergic receptor subtypes and their clinical relevence. November, 1998, Carlsbad, California.

Pharmacology and Cancer Biology Symposium. Mitogenic Signal Transduction in Human Prostate Cancer: Potential Targets for Therapuetic Intervention. January, 1999. Durham, North Carolina.

Duke Urology Assembly. Relative Merits of Continent and Incontinent Urinary Diversions. St. Thomas, Virgin Islands. March 1999.

American Urological Diseases Postgraduate Course. Pharmacologic management of BPH. Faculty Speaker of the AUA. May, 1999. Dallas, Texas.

Society of Basic Urological Research. Adrenergic Receptor Signal Transduction Pathways. June, 1999. Dallas Texas.

Boehringer Ingelheim Speaker Meeting. Alpha1D Adrenergic receptor subtype in LUTS: A review of the current literature. March, 2000, Cancun, Mexico.

Yamanuchi Pharmaceutical Symposium at the American Urological Association Annual Meeting. The role of α1ARs in LUTS. May, 2000, Atlanta, Georgia.

Triangle Urology Association. F18-Choline: a novel PET radiopharmaceutical for imaging prostate cancer. June 2000.

Amgen Invitational Seminar. Update on F18-Choline: a novel PET radiopharmaceutical for imaging prostate cancer. Thousand Oaks, California. August 2000.

Atlanta Urology Seminar. Alpha Receptor Antagonists in the treatment of LUTS. Atlanta, Georgia August 26, 2000.

Northeast Section of the American Urological Association Invitational State of Art Lecture. Alpha Receptors and Lower Urinary Tract Symptomatology. Pittsburg, PN September 2000.

Sanofi-Synthelabo Advisory Board for the Development of Alfuzosin. A review of Alpha Blockers. Dallas, Texas September 2000.

Louisiana Urological Association. Prostate Cancer Imaging: Current and Future Technologies. Shreveport, Louisiana March 16, 2001.

American College of Physicians Meeting. Alpha Blockers in the Treatment of BPH. Atlanta, Georgia. March 29, 2001.

Harvard University Symposium on New Insights in Benign Prostatic Hyperplasia. Invited speaker and participant. Alpha Receptor Subtypes in Lower Urinary Symptomatology. March 31, 2001. Boston, Mass

European Urology Association Invited Speaker. Program on BPH. Alpha Receptor Subtypes in Lower Urinary Symptomatology. April 7, 2001. Geneva, Switzerland.

American Society of Clinical Oncology Press Conference. Results of Phase II Clinical Research of Toremifene in the prevention of prostate cancer. Orlando, FL 2005.

American Urological Association National Meeting. Invited speaker. The Successful Surgical Center. San Antonio, TX 2005

East Texas Primary Care Carthage Meeting. Sponsored by University of Texas Health Center at Tyler. Robotic Prostatectomy. 2007.

Good Sheperd Medical Center Grand Rounds. Prostate Cancer and Robotic Surgery. 2007

East Texas Primary Care Carthage Meeting. Sponsored by University of Texas Health Center at Tyler. Robotic Surgery Update. 2010.


Abstracts

  1. Phifer TJ, DT Price, MB Thomas, and WD Grafton: Performance of the Tilt-Disc Valve in the Inferior Vena Cava: An Animal Study. First Congress of the North. American Society of Phlebology, 1989.
  2. Price DT, DA Schwinn, LF Allen, MG Caron, DF Paulson, JW Lomasney, and RJ Lefkowitz: Alpha1-Adrenergic Receptor Subtypes in the Human Prostate. Program of the Western Section of the American Urologic Association, 1992.
  3. Price DT, DA Schwinn, JW Lomasney, LF Allen, MG Caron, and RJ Lefkowitz: Identification, Quantification, and Localization of Three Alpha1 Adrenergic Receptor Subtypes in Human Prostate. Journal of Urology, May 1993.
  4. Price DT, DA Schwinn, J Kim, CC Carson, MG Caron, and RJ Lefkowitz: Alpha1 Adrenergic Receptor Subtype mRNA Expression in Human Corpus Cavernosum. Journal of Urology, May 1993.
  5. Berkowitz D, DT Price, and DA Schwinn: The Distribution of the alpha2 Adrenergic Receptor mRNA in Various Human Tissues: Preliminary studies. Soc. Cardiovasc. Anes., April 1993.
  6. Price DT, DA Schwinn, MG Caron, and RJ Lefkowitz: Tissue Specific Expression of a1-Adrenergic Receptor Subtype mRNAs: Therpapeutic Implications for Targeted Receptor Blockade. Journal of Clinical Investigation, 1993.
  7. Price DT, RJ Lefkowtiz, MG Caron, and DA Schwinn: Alpha1-Adrenergic Receptor mRNA Expression in Human Tissues. FASEB, 1993.
  8. Price DT, RJ Lefkowitz, and DA Schwinn: α1-Adrenergic Receptor Subtype Distribution in Selected Human Tissues. Soc. Cardiovasc. Anes., April 1993.
  9. Price DT, RJ Lefkowitz, and LF Allen.: Role of Adrenergic Receptors in Growth and Differentiation of the Prostate. SPORE Meeting, July 1993.
  10. Kim JH, DT Price, , KC Young, MG Davies, PO Hagen, and CC Carson: Pharmacologic Classification of Alpha1-Adrenergic Receptor Subtypes in Human Corpus Cavernosum. Program of the Basic Science Session of AUA, 1993.
  11. Berkowitz D, DT Price, and DA Schwinn: The Distribution of the alpha2 Adrenergic Receptor mRNA in Various Human Tissues. Anesthesiology, 1993.
  12. Berkowitz D, D.T. Price, J.H. Kim, and D.A. Schwinn: The Expression of Constitutive Endothelial Nitric Oxide Synthase in Normal Human Myocardium: Nitric Oxide as a Possible Signal Transduction Pathway in Regulating Myocardial Function. Anesthesiology,1994.
  13. Chari R.S, D.T. Price, S.R. Sue, R.L. Jirtle, and W.C. Meyers: Transcriptional Downregulation of Transforming Growth Factor β (TGFβ) Receptor Types I, II, and III Provide a Growth Advantage for Hepatocytes After Partial Hepatectomy. 1993.
  14. Chari R.S., D.T. Price, S.R. Sue, R.L. Jirtle, and W.C. Meyers: Alpha1-Adrenergic Receptor Subtype Expression in Hepatocellular Carcinoma. Program of the International Hepato-Biliary-Pancreatic Association. May, 1993.
  15. Price DT, RS Chari, S Eubanks, T Pappas, and GM Preminger: An Automatic Laparoscopic Suturing Device. Program of the Southeast Section of the American Urological Association, 1994.
  16. Price DT, RS Chari, S Eubanks, TN Pappas, and GM Preminger: Enhanced Tissue Approximation with an Automatic Endoscopic Suturing Device. Journal of Urology 1994.
  17. Price DT, RS Chari, JN Neighbors, S Eubanks, TN Pappas, WW Schuessler, DF Paulson, and GM Preminger: Laparoscopic radical prostatectomy in the canine model. Journal of Endourology, 8: A03-34, 1994.
  18. Lacey J, C Donatucci, DT Price, S Page, M Kwatra, D Schwinn, S Bennett, and M Tenniswood: Regulation of prostate α1-adrenergic receptors by androgens. Journal of Urology,1996
  19. Price DT, J Vieweg, F Roland, L Coetzee, C Iselin and DF Paulson: Transient lower extremity neuropraxia associated with radical perineal prostatectomy: A complication of the exaggerated lithotomy position. Presented at AUA, New Orleans, Louisiana. Journal of Urology, A,97.
  20. Malloy BJ, DT Price, RR Price, AM Bienstock, MK Dole, BL Funk, CF Donatucci, and DA Schwinn: Alpha1 Adrenergic receptor subtypes in human detrusor. Journal ofUrology, A, 1998
  21. Henry GD, Iselin CE, Madden J, Lacey J, Price D, and CF Donatucci: Effect of androgen manipulation on the expression of vascular endothelial growth factor (VEGF) and endothelial nitric oxide synthase (eNOS) in rat erectile tissue. 8th World Meeting on Impotence Research & the 11th Symposium on Corpus Cavernosum Revascularization. Amsterdam, The Netherlands.
  22. Price DT, Della Rocca G, Eckhart AD, Guo C, Ballo MS, Daaka Y, Schwinn DA, and LM Luttrell: Increased activation of extracellular signal regulated kinase in human prostate cancer. AACR Proceeding, Special Meeting on Prostate Cancer Biology. Palm Springs, CA. 1998.
  23. Price, DT and Y Daaka. Hyperactivation of mitogen activated kinases in human prostate cancer. SESAUA. 1999.
  24. Dahm P, F Roland, DT Price, S Vaslef, R Moon, G Georgaide, and J Vieweg. Outcome in patients with necrotizing fasciitis of the male genitalia. European Association of Urology XIVth Congress, Stockholm, Sweeden April, 1999.
  25. Price DT, Della Rocca G, Eckhart AD, Guo C, Ballo MS, Daaka Y, Schwinn DA, and LM Luttrell: Increased activation of extracellular signal regulated kinase in human prostate cancer. AUA, 1999. Dallas, Texas.
  26. Yowell CW, P Dahm, JE Tuttle-Newhall, and DT Price. Surgical intensive care outcome of patients undergoing radical cystoprostatectomy. German Urology Association, 1999.
  27. DT Price, KF Pao, C Guo, and Y Daaka.: Survival signaling in androgen independent prostate cancer cells. Surgical Forum, 1999.
  28. W Demark-Wahnefried, DT Price, TJ Polascik, EE Anderson, M Gannon, and R Volmer.: Effects of short-term flaxseed supplementation and fat modification in men with prostate cancer. Cancer Epidemiol Biomarkers Prev. 9:235, 2000.
  29. C Guo, D Geverd, CM Counter and DT Price. Androgen regulation of telomerase activity and expression in prostate cancer. Southeast Section of American Urological Association 2000.
  30. W Demark-Wahnefried, DT Price, TJ Polascik, EE Anderson, CN Robertson, PJ Walther, DF Paulson, M Gannon, and R Volmer.: Short-term flaxseed supplementation and fat restriction in men with prostate cancer: Effects on prostate specific antigen, hormonal factors, and proliferation rates. Abstract # 3029. Proceedings of the American Association for Cancer Research 41:475, 2000.
  31. C Guo, N Hamad, D Geverd, RP Liao, Christopher M. Counter and DT Price. Inhibition of Telomerase Activity unsing a dominant negative construct of hTERT in prostate cancer cell lines. American Urological Association 2000.
  32. C Guo, CM Counter and DT Price. Androgen regulation of telomerase activity and expression in prostate cancer. American Urological Association 2000.
  33. TR DeGrado, RE Coleman, SW Baldwin, MD Orr, CN Robertson, and DT Price. [18F] Flourocholine: A new PET tracer for prostate cancer. American Radiology Association 2000.
  34. JL Flowers, DT Price, RP Liao, ME Wall, MC Wani, G Manikumar, O.M Colvin, DJ Adams. Activity of camptothecin analogues in histocultures of human brain, breast, prostate, and colon tumors as a function of extracellular pH. American Association of Cancer Research, 2000.
  35. W Demark-Wahnefried, DT Price, TJ Polascik, EE Anderson, M Gannon, and R Vollmer. Presurgical fat restriction and flaxseed supplementation among men with prostate cancer: effects on PSA, hormonal factors, and proliferation rates. Abstract #1301. Journal of Urology 163:293, 2000
  36. Levine AM, Iacocca MV, Gregory CW, Lin Y, Whang Y, Mohler JL, and DT Price. Her-2/neu receptor expression in prostate cancer. American Urological Association 2000.
  37. Heimberger AB, GE Archer, DT Price, RE McLendon, AH Friedman, HS Friedman, DD Bigner, and JH Sampson. Systemic administration of an epidermal growth factor receptor (EGFR) specific tyrosine kinase inhibitor is efficacious against EGFR over-expressing intracranial tumors. Surgical Forum, 2000.
  38. W Demark-Wahnefried, DT Price, TJ Polascik, EE Anderson, CN Robertson, P Walther, DF Paulson, M Gannon, and R Vollmer. Fat restriction & flaxseed supplementation in men with prostate cancer: effects on prostate specific antigen, hormonal and histopathological markers. Jour Amer Diet Assn 100:A-21, 2000.
  39. TR DeGrado, RE Coleman, DT Price, MD Orr, T Polascik, CN Robertson, SW Baldwin. [18F] Flourocholine: A new PET tracer for prostate cancer. American Radiology Association 2000.
  40. W Demark-Wahnefried, DT Price, TJ Polascik, EE Anderson, CN Robertson, P Walther, DF Paulson, M Gannon, and R Vollmer. Presurgical fat restriction and flaxseed supplementation among men with prostate cancer: effects on PSA, hormonal factors and proliferation rates. J Nutrition, 2000.
  41. TR DeGrado, RP Liao, MD Orr, S Wang, D Price SW Baldwin, and E Coleman. F-18 Labeled Choline Analogs as PET Imaging Probes of Prostate Cancer. American Urological Association, Anaheim, CA 2001.
  42. DT Price,B Stein, E Goluboff, P Sieber, D Bostwick, G Barnette, R Boger, and MS Steiner. Double-Blind, Placebo-Controlled Trial of Toremifene for the Prevention of Prostate Cancer in Men with High-Grade Prostatic Intraepithelial Neoplasia. American Society of Clinical Oncology, Orlando, FL 2005
  43. DT Price,B Stein, E Goluboff, P Sieber, D Bostwick, G Barnette, R Boger, and MS Steiner. Double-Blind, Placebo-Controlled Trial of Toremifene for the Prevention of Prostate Cancer in Men with High-Grade Prostatic Intraepithelial Neoplasia. American Urological Association, San Antonio, TX 2005
  44. DT Price, RS Israeli, R Boger, MS Steiner. Concentration-Dependent Estrogen Receptor Binding Profile of Toremifene May Account for its Clinical Dose-Response Profile. American Urological Association, San Antonio, TX 2005
  45. DT Price. Robotic Assisted Laparoscopic Prostatectomy: The evaluation of surgical margin positive rates as a function of the learning curve. Podium Presentation at SESAUA. Orlando, Florida 2007
  46. DT Price. A Comparison of Radical Perineal, Retropubic and Robotic Assisted Laparoscopic Prostatectomy Margin Status in a Large Community Practice: The Value of Subspecialization in the Community Practice. . Podium Presentation at SESAUA. Orlando, Florida 2007
  47. DT Price et al. Robotic Assisted Laparoscopic Partial Nephrectomy in a Community Practice Setting. Podium Presentation at SESAUA. Mobile Alabama 2009.


Manuscripts Published

  1. Phifer TJ, DT Price, MB Thomas, and WD Grafton: Performance of the Tilt-Disc Valve in the Inferior Vena Cava: An Animal Study. Vascular Surgery, 24: 496-502, 1990.
  2. Price DT, DA Schwinn, JW Lomasney, LF Allen, MG Caron, and RJ Lefkowitz: Identification, Quantification, and Localization of the mRNA for Three Alpha1 Adrenergic Receptor Subtypes in Human Prostate. Journal of Urology, 150:546-551, 1993. Montegue Boyd Essay Contest Second Place-1993.
  3. Berkowitz DE, DT Price, SO Page, and DA Schwinn: Localization of mRNA for Three Distinct α2-Adrenergic Receptor Subtypes in Human Tissues: Evidence for Species Heterogeneity and Implications for Human Pharmacology. Anesthesiology, 81:1235-1244, 1994. Essay Contest Winner-1993.
  4. Price DT, K Maloney, and EE Anderson.: Vesical Endometriosis. Urology, 48:639- 643, 1996.
  5. Price DT, RS Chari, JN Neighbors, S Eubanks, WW Schuessler, and GM Preminger: Laparoscopic radical prostatectomy in the canine model. Journal of Laparoendoscopic Surgery, 6:405-412,1996.
  6. Iselin CE, JE Robertson, LJ Layfield, C Cirrincione, DT Price, and DF Paulson: Percent prostate involved by tumor and the Gleason Grading system as predictors of biochemical failure after radical prostatectomy. Urology, 1997.
  7. Malloy BJ, DT Price, RR Price, AM Bienstock, MK Dole, BL Funk, CF Donatucci, and DA Schwinn: Alpha1 Adrenergic receptor subtypes in human detrusor. Journal of Urology, 160:937-943 1998.
  8. Price DT, J Vieweg, F Roland, C Iselin, L Coetzee, and DF Paulson: Transient lower extremity neuropraxia following radical perineal prostatectomy: a complication of the exaggerated lithotomy position. Journal of Urology 160:1376-1378, 1998.
  9. Dahm P, S Szukala, RR Byrne, and DT Price.: Giant hepatoid yolk sac tumor in an adult African-American male. Journal of Urology 162:801-802,1999.
  10. Goepel M, S Krege, DT Price, DA Schwinn, and MC Michel: Characterization of α-adrenoceptor subtypes in the human corpus cavernosum. Journal of Urology 162:1793-1799, 1999.
  11. Ahearne G, R Bedlack, DT Price, CN Robertson, and J Morganlander.: Lumbosacral polyradiculopathy in spinal stenosis. Southern Medical Journal 92:809-811, 1999.
  12. Price DT, GD Rocca, C Guo, MS Ballo, DA Schwinn and LM Luttrell. Activation of extracellular signal regulated kinase in human prostate cancer. Journal of Urology 162:1537-1542, 1999. Montegue Boyd Essay Contest Second Place-1999.
  13. Guo C, LM Luttrell, and DT Price. Mitogenic signaling in androgen sensitive and insensitive prostate cancer cells. Journal of Urology163:1027-1032 2000.
  14. Dahm P, JE Tuttle-Newhall, CW Yowell, RR Byrne, and DT Price.: Prediction of postoperative surgical intensive care unit course of urologic patients. Urology 55:334-338, 2000. Selected as a CME article.
  15. Dahm P, FH Roland, SN Vaslef, RE Moon, DT Price, GS Georgiade, and J Vieweg.: Outcome analysis in patients with primary necrotizing fasciitis of the male genitalia. Urology 56:31-36, 2000.
  16. AM Levine, MV Iacocca, CW Gregory, Y Lin, YE Whang, DT Price, and JL Mohler.: HER-2/neu receptor expression in prostate cancer. Urology, Submitted 2000, accepted with revisions
  17. Price DT, X Rudner, G Michelotti, M Smith, and DA Schwinn. Immortalization of a human prostate stromal cell line using a recombinant retroviral approach. Journal of Urology164: 2145-2150, 2000.
  18. R Munver and DT Price. Acute corticosteroid induced hemorrhage arising from an ileal loop ulcer in a patient with idiopathic thrombocytopenic purpura. Journal of Urology 164:1300-1301, 2000.
  19. Michelotti GA, DT Price, DA Schwinn: Regulation of Alpha-1 Adrenergic Receptor Function. Pharmacology and Therapeutics 88:281-309, 2000.
  20. Coleman R, DeGrado T, Wang S, Baldwin S, Orr M, Reiman R, and D Price. Preliminary evaluation of F-18 Fluorocholine (FCH) as a PET tumor imaging agent. Clin Positron Imaging 3:147,2000.
  21. Sekula JJ, RP Liao, J Madden and DT Price. Transitional Cell Carcinoma in a Prostatic Remnant Ten Years Following Radical Cystectomy. Journal of Urology 165:1222,2001
  22. C Guo, N Hamad, D Geverd, RP Liao, Christopher M. Counter and DT Price. Inhibition of telomerase is related to the life span and tumorigenicity of human prostate cancer cells. Journal of Urology166:694-698, 2001.
  23. TR DeGrado, RE Coleman, S Wang, SW Baldwin, MD Orr, CN Robertson, TJ Polascik, RE Reiman and DT Price. Synthesis and evaluation of 18F-labeled choline as an oncologic tracer for positron emission tomography: initial findings in prostate cancer. Cancer Research 61:110-117, 2001.
  24. L Hale, DT Price, W Demark-Wahnefried and J Madden. Zinc alpha-2-glycoprotein expression in normal and malignant prostate tissues. Clinical Cancer Research 7:846-853, 2001.
  25. P Dahm, JE Tuttle-Newhall, CW Yowell, and DT Price. Indications for admission to the surgical intensive care unit (SICU) following radical cystectomy and urinary diversion. Journal of Urology 166:189-193, 2001.
  26. W Demark-Wahnefried, DT Price, TJ Polascik, EE Anderson, M Gannon, and R Vollmer. Effects of short-term flaxseed supplementation and fat modification in men with prostate cancer. Urology 58:47-52, 2001.
  27. GV Raj, SK Pruitt, S Lilly, JT Madden, and DT Price. Multimodality therapy for Adult Wilms Tumor stage IV. Journal of Urology 165:1202, 2001.
  28. TR DeGrado, SW Baldwin, S Wang, MD Orr, RP Liao, HS Friedman, R Reiman, DT Price, and RE Coleman. Synthesis and evaluation of F18-labeled choline analogs as oncologic PET tracers. Journal of Nuclear Medicine 42:1805-1814, 2001, (See also editorial by Hara pages 1815-1817).
  29. DA Schwinn, DT Price, and P Narayan. Subtype selectivity of alpha-adrenoceptors and its role in Benign Prostatic Hypertrophy. American Journal of Medicine, in press.
  30. DA Schwinn and DT Price. Role and rationale for α-adrenoceptor antagonists as treatment for benign prostatic hyperplasia in hypertensive patients. American Journal of Medicine in press.
  31. Price DT, Potential Mechanisms of Superselective Alpha Adrenergic Antagonists. European Eurology 40:5-11, 2001.
  32. Orr MD, SW Baldwin, DT Price, RE Coleman, RP Liao, and TR DeGrado. Synthesis and evaluation of 18F-labeled choline analogs as oncologic tracers for positron emission tomography of prostate carcinoma. J Med. Chem. Submitted, 2001.
  33. Price DT, RE Coleman, RP Liao, MD Orr, S Wang, SW Baldwin, and TR DeGrado. Comparison of F-18 Fluorocholine and F-18 Fluorodeoxyglucose in positron emission tomography (PET) imaging of androgen-dependent and androgen-independent prostate cancer. Journal of Urology168:273, 2002.
  34. DeGrado TR, RE Reiman, RP Liao, DT Price, S Wang, and RE Coleman. Pharmacokinetics and radiation dosimetry of [18F] Fluorocholine (FCH). J Nucl Med. 43:92-96, 2002.
  35. C Guo, DT Price, CM Counter. In vivo regulation of hTERT expression and telomerase activity by androgens. Journal of Urology 170:615, 2003.
  36. DA Schwinn, Price DT, P Narayan. Alpha Adrenergic Subtypes and Lower Urinary Symptomatology. Mayo Clinic Proced 79:1423, 2004.
  37. R Selvan, Cornforth AN, Price DT, et al. Establishment and characterization of prostate cancer cell line HH870. Prostate 63:91, 2005.
  38. DT Price, B Stein, E Goluboff, P Sieber, D Bostwick, G Barnette, R Boger, and MS Steiner. Double-Blind, Placebo-Controlled Trial of Toremifene for the Prevention of Prostate Cancer in Men with High-Grade Prostatic Intraepithelial Neoplasia. Journal of Urology. 2006.
  39. DT Price. Physician Noncompete Agreements and the Ethical Practice of Medicine. Journal of the Louisiana State Medical Society. Volume 162; 2: 110-113, 2010.
  40. Price DT, RJ Lefkowitz, MG Caron, and DA Schwinn: Localization of mRNA for Three Distinct α1-Adrenergic Receptor Subtypes in Human Tissues: Implications for Human α-Adrenergic Physiology. Molecular Pharmacology, 45:171-175, 1994.
  41. Price DT, RS Chari, DB Berkowitz, WE. Meyers, and DA Schwinn: Alpha1 Adrenergic Receptor Subtype mRNA Expression in Rat Tissues and Human SK-N-MC Neuronal Cells: Implications for merging classic pharmacology with molecular classification schemes. Molecular Pharmacology, 46:221-226, 1994.
  42. Chari, RS, DT Price, SR Sue, RL Jirtle, and WC Meyers: Downregulation of Transforming Growth Factor Beta (TGF β) Receptor Types I, II, and III During Liver Regeneration. American Journal of Surgery, 169:126-132, 1994.
  43. Berkowitz DE, NA Nardone, RM Smiley, DT Price, DK Kreutter, RT Fremeau, and DA Schwinn: The Distribution of β3 Adrenergic Receptor mRNA in Human Tissues.Eur. J. Pharmacol., 289:223-228,1995.
  44. Lacey J, C Donatucci, DT Price, S Page, M Kwatra, DA Schwinn, S Bennett, and M Tenniswood: Regulation of prostate α1-adrenergic receptors by androgens. Urology, 48:335-341, 1996.


Book Chapters

  1. Price, DT and TN Pappas: Training in Advanced Laparoscopic Procedures. In Current Review of Laparoscopy, 2nd Ed., 1995.
  2. Price, DT and CN Robertson: Laparoscopic Pelvic Lymphadenectomy. In Atlas of Laparoscopic Surgery, 23:2-10, 1996.
  3. Byrne RR, P Dahm, and DT Price: Laparoscopic Staging Pelvic Lymphadenectomy for Prostate Cancer. In Atlas of Laparoscopic Surgery, 2nd Ed., 1999.


Clinical Trials

  1. AstraZeneca - Protocol Number 7054US/0009. A randomized trial with Bicalutamide (Casodex ®) 150 mg monotherapy in patients with prostate cancer to determine the reduction of incidence of high grade prostatic intraepithelial neoplasia (HGPIN) prior to radical prostatectomy. Closed
  2. TAP Pharmaceutical Product Inc. - Protocol Number M99-051. A phase II ranndomized-discontinuation study of oral CEP-701 in prostate cancer patients who have failed first-line hormonal therapy. Closed
  3. TAP Pharmaceutical Product Inc. - Protocol Number M99-121. A phase II, long-term, open-label extension study of oral CEP-701 in patients previously receiving CEP-701 for treatment of prostate cancer. Closed
  4. Ortho-McNeil Pharmaceutical - Protocol CAPSS-101. A multi center, double-blind study to compare the safety and efficacy of levofloxacin to that of ciprofloxacin in the treatment of chronic prostatitis. Closed
  5. Pharmacia & Upjohn – Protocol 583E-URO-0084-018. Pharmacokinetics and safety of tolterodine 2 and 4 mg once daily in children 11 through 15 years of age. An open, dose-escalation study in patients with overactive bladder.Closed
  6. Boehringer Ingelheim Pharmaceuticals, Inc. - FlomaxÆ Trial 527.26. A two phase, double-blinded, randomized, parallel-group design, multicenter study of FLOMAXÆ capsules, 0.4 mg versus placebo, in male patients with acute urinary retention related to benign prostatic hyperplasia. Closed
  7. Sanofi-Synthelabo - ALFAURUS Protocol EFC4428. A double-blind randomized parallel group study of Alfuzosin 10 mg OD versus placebo in the management of acute urinary retention in patients with a first episode due to BPH. Closed
  8. Celsion Corporation – Protocol Number 03. A randomized study with microwave uroplasty and Proscar for the treatment of benign prostatic hyperplasia. Closed